Anti-human CCL24 monoclonal antibody (CM-101) - Part One
CM-101-I-002
Phase 1 small_molecule completed
Quick answer
Anti-human CCL24 monoclonal antibody (CM-101) - Part One for Nonalcoholic Fatty Liver Disease is a Phase 1 program (small_molecule) at Chemomab Therapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Chemomab Therapeutics
- Indication
- Nonalcoholic Fatty Liver Disease
- Phase
- Phase 1
- Modality
- small_molecule
- Status
- completed